Abstract:Background & Aims: Despite being a typical oncogene, PIM kinase has been reported to suggest a favorable prognosis in some solid tumors, but no research has yet explored the underlying mechanisms. Furthermore, an inconsistent prognosis also hinders the clinical application of PIM inhibitors. We aimed to explore the clinical significance and regulatory mechanism of PIM2, as well as the potential clinical application of PIM2 inhibitor in hepatocellular carcinoma (HCC). Methods: PIM2 expression was assessed in 464 HCC patients who underwent curative resection, and its correlations with prognosis, immune status, and tumor infiltrating leukocytes (TILs) were investigated. Moreover, the underlying regulatory mechanisms of PIM2 and the clinical application of PIM2 inhibitor were also studied. Results: We found that PIM2 primarily displayed an oncogenic function in HCC. However, elevated PIM2 expression in tumor cells predicted a favorable prognosis. Mechanistically, high PIM2 expression in tumors was associated with an adaptive immune response elicited by TILs, and IL-1β, together with TNF-α and IFN-γ, derived from TILs induced the expression of PIM2 by activating the p38/Erk/MAPK and NF-κB signaling pathways in tumor cells. Specifically, high PIM2 expression in tumors was significantly correlated with a high density of T cells and monocytes, and activated T cell-secreting IFN-γ-polarized monocytes induced the tumor cell PIM2 expression in the tumor milieu. Moreover, blockade of antitumor milieu-induced tumor cell PIM2 expression potently augmented the therapeutic efficacy of anti-PD-L1 therapy in HCC. Conclusions: Our study provides important insights into a possible adaptive immune resistance mechanism by which the antitumor milieu induces oncogenic PIM2 expression in tumor cells. Moreover, specific inhibition of PIM2 in tumor cells augments the therapeutic efficacy of anti-PD-L1 therapy in HCC. Citation Format: Juncheng Wang, Shi-Xun Lu, Jinbin Chen, Dongping Chen, Minshan Chen, Zhongguo Zhou. Blockade of antitumor milieu-induced tumor cell PIM2 expression potently synergizes with anti-PD-L1 therapy in hepatocellular carcinoma [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1690.

Pim-2 Activates API-5 to Inhibit the Apoptosis of Hepatocellular Carcinoma Cells Through NF-κB Pathway

Serine/Threonine Kinase Pim-2 Promotes Liver Tumorigenesis Induction Through Mediating Survival and Preventing Apoptosis of Liver Cell

PIM2 Promotes Hepatocellular Carcinoma Tumorigenesis and Progression Through Activating NF-κB Signaling Pathway.

Inhibition of RIPK 1 expression and facilitation of TRAIL-induced hepatocellular carcinoma cell apoptosis by miR-141

Excessive Activation of HOXB13/PIMREG Axis Promotes Hepatocellular Carcinoma Progression and Drug Resistance

Abstract 1690: Blockade of Antitumor Milieu-Induced Tumor Cell PIM2 Expression Potently Synergizes with Anti-Pd-l1 Therapy in Hepatocellular Carcinoma

CBL0137 Administration Suppresses Human Hepatocellular Carcinoma Cells Proliferation and Induces Apoptosis Associated with Multiple Cell Death Related Proteins.

Downregulation of Peptidylprolyl Isomerase A Promotes Cell Death and Enhances Doxorubicin-Induced Apoptosis in Hepatocellular Carcinoma.

Immunotherapy for Hepatoma Using A Dual-Function Vector with Both Immunostimulatory and Pim-3-Silencing Effects

Pim-3 promotes human pancreatic cancer growth by regulating tumor vasculogenesis.

Role of the Death Receptor and Endoplasmic Reticulum Stress Signaling Pathways in Polyphyllin I-Regulated Apoptosis of Human Hepatocellular Carcinoma HepG2 Cells

Dual Role of PID1 in Regulating Apoptosis Induced by Distinct Anticancer-Agents Through AKT/Raf-1-dependent Pathway in Hepatocellular Carcinoma

Pyruvate Kinase M2 Prevents Apoptosis Via Modulating Bim Stability and Associates with Poor Outcome in Hepatocellular Carcinoma.

[Inhibitive Mechanisms of Pim-3 Affecting Fulminant Hepatic Apoptosis].

Ponicidin Promotes Hepatocellular Carcinoma Mitochondrial Apoptosis by Stabilizing Keap1‐PGAM5 Complex

Hepatopoietin Cn Suppresses Apoptosis of Human Hepatocellular Carcinoma Cells by Up-Regulating Myeloid Cell Leukemia-1.

PIM2 expression induced by proinflammatory macrophages suppresses immunotherapy efficacy in hepatocellular carcinoma

PP2A Inhibitors Trigger Apoptosis of Pancreatic Cancer PANC-1 Cells Through Nuclear Factor-Κb-dependent Pathway

Supplementary Figure 2 from Immunotherapy for Hepatoma Using a Dual-Function Vector with Both Immunostimulatory and Pim-3–Silencing Effects

Pim-2 Protects H9c2 Cardiomyocytes Fromhypoxia/reoxygenation-Induced Apoptosis Via Downregulation of Bimexpression.

Inhibition of CIP2A Attenuates Tumor Progression by Inducing Cell Cycle Arrest and Promoting Cellular Senescence in Hepatocellular Carcinoma